Literature DB >> 31480058

Impact of Early Vitrectomy for Dense Vitreous Hemorrhage of Unknown Etiology.

Mayuka Hayashida1, Akiko Miki2, Hisanori Imai1, Keiko Otsuka1, Atsushi Azumi3, Makoto Nakamura1.   

Abstract

BACKGROUND: Surgical intervention for dense vitreous hemorrhage (DVH) with unclear etiology is often delayed in favor of conservative follow-up despite possible disease progression and the availability of safe minimally invasive vitrectomy.
OBJECTIVES: The aim of this study is to investigate the efficacy of early surgical intervention for DVH with unknown etiology.
METHODS: Eighty-eight cases (88 eyes) of DVH with unknown origin were retrospectively reviewed. Inclusion criteria were as follows: (1) measured visual acuity (VA) of 20/200 or worse and (2) fundus invisibility requiring B-scan ultrasonography. Eyes with a history of diabetic retinopathy, recent trauma, or likely retinal detachment (RD) as revealed by B-scan ultrasonography were excluded. Outcome measures were a cause of vitreous hemorrhage and final VA following early (≤2 weeks after symptom onset) or delayed vitrectomy.
RESULTS: The most frequently occurring causes of DVH were central or branch retinal vein occlusion (30 eyes, 34%) and retinal tear or RD (29 eyes, 33%). logMAR VA significantly improved after treatment (p < 0.001). Final VA was significantly higher for eyes treated within 2 weeks compared with eyes treated later than 2 weeks after symptom onset (p = 0.020).
CONCLUSIONS: Surgical intervention within 2 weeks after symptom onset may prevent a lower visual outcome.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Retinal detachment; Retinal vein occlusion; Vitrectomy; Vitreous hemorrhage

Mesh:

Year:  2019        PMID: 31480058     DOI: 10.1159/000501723

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  1 in total

Review 1.  [Vitreous body hemorrhage-How long can one wait?]

Authors:  Felix Treumer; Johann Roider
Journal:  Ophthalmologe       Date:  2020-09       Impact factor: 1.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.